Compile Data Set for Download or QSAR
Report error Found 103 Enz. Inhib. hit(s) with all data for entry = 10554
TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318866(US10172868, Compound C001 | N-(3-(2-((4-morpholino...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318867(US10172868, Compound C003 | N-(3-(2-((2-methoxy-4-...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:EGFR: The 2×EGFR (ErbB1)/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:BTK: The 2×BTK/Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:FGFR1: The 2×FGFR1/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:FGFR2: The 2×FGFR2/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:KDR: The 2×KDR (VEGFR2)/Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:JAK3: The 2×JAK3/Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318869(US10172868, Compound C032 | N-(3-(2-((4-(4-acetylp...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Neupharma

US Patent
LigandPNGBDBM318870(US10172868, Compound C034 | N-(3-(7-methyl-2-((4-(...)
Affinity DataIC50: 100nMAssay Description:EGFR: The 2×EGFR (ErbB1)/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318870(US10172868, Compound C034 | N-(3-(7-methyl-2-((4-(...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Neupharma

US Patent
LigandPNGBDBM318871(US10172868, Compound C040 | N-(5-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:EGFR: The 2×EGFR (ErbB1)/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318871(US10172868, Compound C040 | N-(5-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Neupharma

US Patent
LigandPNGBDBM318872(US10172868, Compound C041 | N-(3-(2-((6-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:EGFR: The 2×EGFR (ErbB1)/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318872(US10172868, Compound C041 | N-(3-(2-((6-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM318872(US10172868, Compound C041 | N-(3-(2-((6-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:BTK: The 2×BTK/Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Neupharma

US Patent
LigandPNGBDBM318872(US10172868, Compound C041 | N-(3-(2-((6-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:FGFR1: The 2×FGFR1/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM318872(US10172868, Compound C041 | N-(3-(2-((6-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:KDR: The 2×KDR (VEGFR2)/Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Neupharma

US Patent
LigandPNGBDBM318872(US10172868, Compound C041 | N-(3-(2-((6-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:JAK3: The 2×JAK3/Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Neupharma

US Patent
LigandPNGBDBM318873(US10172868, Compound C044 | N-(3-(2-((2-fluoro-4-(...)
Affinity DataIC50: 100nMAssay Description:EGFR: The 2×EGFR (ErbB1)/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318873(US10172868, Compound C044 | N-(3-(2-((2-fluoro-4-(...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM318873(US10172868, Compound C044 | N-(3-(2-((2-fluoro-4-(...)
Affinity DataIC50: 100nMAssay Description:BTK: The 2×BTK/Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Neupharma

US Patent
LigandPNGBDBM318873(US10172868, Compound C044 | N-(3-(2-((2-fluoro-4-(...)
Affinity DataIC50: 100nMAssay Description:JAK3: The 2×JAK3/Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318874(US10172868, Compound C045 | N-(2-fluoro-3-(2-((4-(...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Neupharma

US Patent
LigandPNGBDBM318875(US10172868, Compound C048 | N-(2-fluoro-3-(2-((6-(...)
Affinity DataIC50: 100nMAssay Description:EGFR: The 2×EGFR (ErbB1)/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318875(US10172868, Compound C048 | N-(2-fluoro-3-(2-((6-(...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318876(US10172868, Compound C049 | N-(3-(2-((4-(4-acetylp...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318877(US10172868, Compound C054 | N-(2-chloro-3-(2-((4-(...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM549532(N-(4-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)q...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Neupharma

US Patent
LigandPNGBDBM318879(US10172868, Compound C059 | N-(3-(2-((4-(4-(2-hydr...)
Affinity DataIC50: 100nMAssay Description:EGFR: The 2×EGFR (ErbB1)/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318879(US10172868, Compound C059 | N-(3-(2-((4-(4-(2-hydr...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM318879(US10172868, Compound C059 | N-(3-(2-((4-(4-(2-hydr...)
Affinity DataIC50: 100nMAssay Description:BTK: The 2×BTK/Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Neupharma

US Patent
LigandPNGBDBM318879(US10172868, Compound C059 | N-(3-(2-((4-(4-(2-hydr...)
Affinity DataIC50: 100nMAssay Description:FGFR1: The 2×FGFR1/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM318879(US10172868, Compound C059 | N-(3-(2-((4-(4-(2-hydr...)
Affinity DataIC50: 100nMAssay Description:KDR: The 2×KDR (VEGFR2)/Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Neupharma

US Patent
LigandPNGBDBM318879(US10172868, Compound C059 | N-(3-(2-((4-(4-(2-hydr...)
Affinity DataIC50: 100nMAssay Description:JAK3: The 2×JAK3/Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318880(US10172868, Compound C061 | N-(2-fluoro-3-(2-((4-(...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318881(US10172868, Compound C063 | N-(2-methoxy-3-(2-((4-...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318882(US10172868, Compound C067 | N-(4-fluoro-3-(2-((4-(...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318883(US10172868, Compound C068 | N-(2-cyano-3-(2-((4-(4...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318884(US10172868, Compound C072 | N-(3-(2-((3-chloro-4-(...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318885(US10172868, Compound C074 | N-(3-(2-((3-cyano-4-(4...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318886(US10172868, Compound C075 | N-(3-(2-((3-methoxy-4-...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM549541(N-(3-(2-((4-(3-(hydroxymethyl)-4-methylpiperazin-1...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318888(US10172868, Compound C078 | N-(3-(2-((4-((1-(2-flu...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318889(US10172868, Compound C079 | N-(3-(2-((4-((3-fluoro...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM318889(US10172868, Compound C079 | N-(3-(2-((4-((3-fluoro...)
Affinity DataIC50: 100nMAssay Description:BTK: The 2×BTK/Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318890(US10172868, Compound C080 | N-(2-fluoro-3-(2-((4-(...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318891(US10172868, Compound C081 | N-(3-(2-((5-chloro-6-(...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318892(US10172868, Compound C085 | 5-((8-(3-acrylamidophe...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 103 total ) | Next | Last >>
Jump to: